Story perspectives

60mg Admilparant Slows Lung-Function Decline in IPF Trial

By Drooid · Oct 13, 2026, 3:40 PM UTC · How we work

Summary

Story summary

Bristol Myers Squibb reported a 60 mg admilparant dose slowed lung-function decline in idiopathic pulmonary fibrosis.
The ALOFT-IPF trial enrolled about 1,255 patients, comparing two doses with placebo for 52 weeks.
The 120 mg dose failed to reach statistical significance versus placebo on the primary lung-function endpoint.
Both doses were well-tolerated, with discontinuation rates similar to placebo.
The company will seek regulatory approval and expects a companion trial readout in early 2027.

1 of 1

Story summary

Bristol Myers Squibb reported a 60 mg admilparant dose slowed lung-function decline in idiopathic pulmonary fibrosis.
The ALOFT-IPF trial enrolled about 1,255 patients, comparing two doses with placebo for 52 weeks.
The 120 mg dose failed to reach statistical significance versus placebo on the primary lung-function endpoint.
Both doses were well-tolerated, with discontinuation rates similar to placebo.
The company will seek regulatory approval and expects a companion trial readout in early 2027.